E7070

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Colorectal Cancer

Conditions

Colorectal Cancer

Trial Timeline

Apr 1, 2005 → —

NCT ID

NCT00165867

About E7070

E7070 is a phase 2 stage product being developed by Eisai for Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00165867. Target conditions include Colorectal Cancer.

What happened to similar drugs?

15 of 20 similar drugs in Colorectal Cancer were approved

Approved (15) Terminated (3) Active (4)

✅Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2MerckApproved

✅Cetuximab (EGFR inhibitor) + Bevacizumab + Irinotecan (CPT-11) + Oxaliplatin + Leucovorin and 5-FU + CapecitabineMerckApproved

✅5-FU based doublet chemotherapy + bevacizumabRocheApproved

✅capecitabine [Xeloda]RocheApproved

✅5-Fluorouracil + Bevacizumab + Irinotecan + OxaliplatinRocheApproved

✅Oxaliplatin + Capecitabine + Bevacizumab + Leucovorin + 5-Fluouracil + IrinotecanRocheApproved

✅CapecitabineRocheApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00165867	Phase 2	Completed	Apr 1, 2005	—	Colorectal Cancer
NCT00165594	Phase 1/2	Terminated	Feb 1, 2005	Aug 1, 2006	Gastric Cancer
NCT00165880	Phase 2	Terminated	Dec 1, 2004	Sep 1, 2007	Metastatic Breast Cancer
NCT00080197	Phase 2	Completed	Feb 1, 2004	May 1, 2005	Breast Neoplasms
NCT00165854	Phase 2	Completed	Mar 1, 2003	—	Colorectal Cancer (CRC)
NCT00059735	Phase 2	Completed	May 1, 2002	Dec 1, 2003	Kidney Neoplasms

Competing Products

20 competing products in Colorectal Cancer

See all competitors

Product	Company	Stage	Hype Score
Cetuximab + Oxaliplatin + Capecitabine	Eli Lilly	Phase 2	35
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FU	Eli Lilly	Phase 2	35
ZN-c3 + Encorafenib + Cetuximab	Zentalis Pharmaceuticals	Phase 1	11
ALIMTA + Oxaliplatin	Eli Lilly	Phase 2	35
eFT508 + Avelumab	eFFECTOR Therapeutics	Phase 2	25
Bevacizumab + Oxaliplatin + Capecitabine	Chugai Pharmaceutical	Phase 1/2	32
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + Capecitabine	Chugai Pharmaceutical	Phase 2	31
FOLFIRI + FOLFOX-4 + FOLFIRI-HD + FOLFOX-7 + FOLFIRINOX	Chugai Pharmaceutical	Phase 2/3	38
Gemcitabine and UFTE chemotherapy	Yuhan	Phase 2	35
CPT-11 and TS-1 + CPT-11, 5-FU and l-LV	Daiichi Sankyo	Phase 2/3	38
CPT-11 based regimens	Daiichi Sankyo	Pre-clinical	26
CS7017 + irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)	Daiichi Sankyo	Phase 2	35
Tivantinib + Placebo + Cetuximab + Irinotecan	Daiichi Sankyo	Phase 1/2	32
DS-8201a 5.4 mg/kg Q3W + DS-8201a 6.4 mg/kg Q3W	Daiichi Sankyo	Phase 2	35
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	39
CS-1008 + irinotecan	Daiichi Sankyo	Phase 2	27
CS-7017 + Placebo	Daiichi Sankyo	Phase 2	27
Patritumab Deruxtecan	Daiichi Sankyo	Phase 2	27
CS-1008 + FOLFIRI	Daiichi Sankyo	Phase 1	29
DS-8273a + nivolumab	Daiichi Sankyo	Phase 1	21